The Asthma Landscape in America Today
More than 26 million Americans live with asthma, according to data from national health surveys. That is roughly 8.2% of the population. About 4.5 million of those are children under 18. The numbers have not budged dramatically in recent years, but the treatment landscape certainly has. Biologic medications—drugs that target specific immune pathways—have rewritten the playbook for people with moderate to severe asthma.
Still, many patients cycle through inhalers and oral steroids without ever reaching the level of control they deserve. Some experience side effects from long-term corticosteroid use that become problems of their own. Others have asthma that does not fit neatly into the allergic or eosinophilic categories that most biologics target. This is where clinical trials enter the picture. They are not just experiments; for a lot of people, they are a chance to access therapies years before they reach the pharmacy shelf.
Why Clinical Trials Exist and How They Work
Every medication on the market, from the albuterol in your rescue inhaler to the newest biologic injection, once passed through a clinical trial. The process is built around one question: does this treatment work, and is it safe?
Trials happen in phases. Phase I studies are small and focus on safety. Phase II expands the participant pool and starts to measure effectiveness. Phase III trials enroll hundreds or thousands of patients across multiple sites—often including community clinics and academic hospitals—and generate the data that regulators review. Phase IV, sometimes called post-marketing studies, continues after a drug is already available, gathering real-world evidence on how it performs in broader populations. A recent example is the PASSAGE study, a Phase IV trial evaluating tezepelumab across different asthma subtypes and in groups often underrepresented in earlier research, including Black Americans and adolescents.
Understanding this structure matters because it tells you where a trial sits on the risk spectrum. A Phase III trial for a drug that has already shown promise in earlier stages carries a different weight than a first-in-human Phase I study.
Types of Asthma Clinical Trials
Not all asthma trials test new pills or injections. The range is broader than most people assume.
Biologic therapy trials dominate the current landscape. These investigate monoclonal antibodies that block specific inflammatory signals—like interleukin-4, interleukin-5, or thymic stromal lymphopoietin, often called TSLP. If you have heard of dupilumab, mepolizumab, or tezepelumab, you already know the names of biologics that started in trials. Newer ones are still being tested, including combinations that target multiple pathways at once.
Inhaler and delivery device trials look at new combinations of existing drugs or new ways to deliver them. In April 2026, a triple-combination inhaler called Breztri—containing a corticosteroid, a long-acting beta agonist, and a long-acting muscarinic antagonist—received regulatory approval for asthma in patients 12 and older. This was based on the KALOS and LOGOS Phase III trials, and it marked the first single-inhaler triple therapy available for asthma in the United States. Trials like these matter because simplifying a treatment regimen from multiple inhalers to one can improve adherence.
Lifestyle and behavioral intervention trials test non-drug approaches. Some studies examine whether weight loss programs, breathing techniques, or environmental modifications can reduce exacerbation rates. The TRIM trial, for example, is investigating whether roflumilast—a drug originally used for COPD—can help people with poorly controlled asthma and elevated body weight.
Pediatric and adolescent trials deserve special attention. Children are not small adults when it comes to asthma, and treatments that work for older populations need separate evaluation. The recent Breztri approval included adolescents 12 and up, which reflects a growing emphasis on generating data for younger age groups.
Here is a quick look at how different categories of asthma trials compare:
| Trial Type | Typical Duration | Who It May Suit | Key Considerations |
|---|
| Biologic therapy (Phase III) | 6 to 24 months | Moderate to severe eosinophilic or allergic asthma | Requires regular injections; may reduce oral steroid use |
| New inhaler combinations | 3 to 12 months | Mild to moderate persistent asthma | Often compares new combo to existing treatments |
| Lifestyle/behavioral | 3 to 12 months | Overweight patients or those with specific triggers | Non-drug approach; may require frequent clinic visits |
| Pediatric-focused | 6 to 24 months | Children and teens under 18 | Requires parental consent; design adapted for younger patients |
| Phase IV real-world studies | 12 to 52 weeks | Broad populations, including previously excluded groups | Drug already approved; focus on real-world effectiveness |
Finding a Trial That Fits
The most direct route is ClinicalTrials.gov, a database maintained by the National Institutes of Health. You can search by condition, location, age group, and trial phase. Typing "asthma" and your city or state into the search bar will pull up recruiting studies near you. Many academic medical centers—places like Duke, Northwestern, the University of Arizona, and Mount Sinai—run dedicated asthma research programs and list their actively recruiting trials on their websites.
The American Lung Association also maintains a clinical trial finder through its Airways Clinical Research Centers network. Their TRIM study, for instance, is recruiting at five locations across the country, including sites in Arizona, Illinois, New York, North Carolina, and Vermont. Each listing includes a phone number and email for the research coordinator, which makes the first step as simple as a phone call.
Community allergists and pulmonologists are another underused resource. Many private practices serve as trial sites or can refer patients to nearby academic centers. If you already see a specialist, asking whether they know of any recruiting studies can open doors you might not find through online searches alone.
What to Expect if You Enroll
The first visit is almost always a screening appointment. You will undergo breathing tests, possibly blood work, and a review of your medical history. The research team needs to confirm that you meet the trial's inclusion criteria—things like age, asthma severity, current medications, and specific biomarkers like blood eosinophil counts.
If you qualify, you will sign an informed consent document that spells out every detail: how many visits are required, what procedures you will undergo, the potential risks and benefits, and how your data will be used. Read this carefully. Ask questions. A good research coordinator will welcome them.
During the trial, you might receive the study drug or a placebo, depending on the design. Many asthma trials are double-blind, meaning neither you nor the research team knows which you are getting. This can feel unsettling, but it is how the science stays honest. Some trials include an open-label extension phase, where everyone receives the active treatment after the blinded portion ends.
Side effects are possible with any investigational therapy. The research team monitors you closely, and you will have a direct line to someone who can address concerns. If something feels wrong, you report it immediately. You can also withdraw from a trial at any point, for any reason.
Travel costs and time commitments vary. Some studies reimburse participants for mileage, parking, and sometimes lodging if the site is far from home. The specifics depend on the sponsor and the trial. During the screening process, ask the coordinator directly about what compensation or reimbursement is available. You should not be left guessing about out-of-pocket costs.
Maria, a 42-year-old from Tucson who enrolled in a biologic trial after years of oral steroid dependence, described the experience this way: "I was nervous about the unknown, but the team walked me through every step. Within a few months, my nighttime symptoms dropped enough that I could sleep through the night for the first time in years." Her story is not unique. Many participants report that the structured, attentive care they receive during a trial—frequent check-ins, detailed monitoring, access to specialists—becomes a benefit in itself.
For others, the motivation is less personal. David, a retired teacher in Chicago, joined a trial because his granddaughter has severe asthma. "If the data from my participation helps a researcher understand this disease better, that is enough for me," he said.
Taking the Next Step
Asthma clinical trials are not a last resort. They are a legitimate treatment option that sits alongside—not beneath—standard care. The decision to participate is personal and should involve conversations with your family, your primary care provider, and the research team.
Start by searching ClinicalTrials.gov or the American Lung Association's trial finder. Narrow your results by location and read the eligibility criteria carefully. If something looks promising, call or email the coordinator listed on the study page. That first conversation is low-pressure and informational. You are not committing to anything by asking questions.
The treatments that will define asthma care a decade from now are being studied today. Whether you participate for your own health, for the sake of others, or a mix of both, you become part of something larger than a single study. You help build the evidence that lets future patients breathe easier.
研究の知恵